Effect of Shengmai capsule adjuvant therapy on cardiopulmonary function,whole blood viscosity and adverse events in patients with COPD complicated with pulmonary heart disease

WU Di; YAN Xiao-ying; YANG Hai-bo; CHEN Wei-xiang; CHEN Wei

doi:10.3969/j.issn.1672-8157.2023.04.007

Abstract：Objective:To explore the effects of Shengmai capsule adjuvant therapy on cardiopulmonary function,whole blood viscosity and adverse events in patients with chronic obstructive pulmonary disease(COPD)complicated with pulmonary heart disease.Methods:In this study,100 patients with COPD and pulmonary heart disease in the Fourth People's Hospital of Tongxiang were randomized into the control group and study group with 50 in each group.The patients in the control group received conventional treatment including diuresis,resolving phlegm,anti-infection and oxygen inhalation,etc,and those in the study group took Shengmai capsule on the basis of the control group for 1 month and followed up for 3 months.Comparison of RVSP,PASP,LVEF,FVC,FEV1,FEV1/FVC,whole blood viscosity and fibrinogen at different time points before and after the treatment was conducted between the 2 goups.Meanwhile,the cumulative incidence of adverse events after 3 months of follow-up was compared between the 2 groups.Results:Compared with the control group,the total effective rate of the study group was significantly higher(P<0.05).RVSP was decreased and LVEF and PASP were increased in both groups after treatment.Compared with the control group after treatment,RVSP was lower and PASP and LVEF were higher in the study group(P<0.05).FVC,FEV1 and FEV1/FVC were increased and the team's three indicators had a higher value after treament in both groups(P<0.05).The two groups had lower whole blood viscosity and fibrinogen after treatment and comparison showed that these 2 indexes were significantly lower in the study group than in the control(P<0.05).The cumulative incidence of adverse events in the control group was 26.00%(13/50),which was significantly higher than 6.00%(3/50)of the study group(P<0.05).Conclusion:The application of Shengmai capsule in the adjuvant treatment of COPD patients with pulmonary heart disease can significantly improve the clinical treatment effect of patients,improve the cardiopulmonary function index and whole blood viscosity,reduce the incidence of cumulative adverse events.So it has high clinical efficacy and safety.